EMA Authorised: Kiovig (human normal immunoglobulin (IVIg)) — Takeda Manufacturing Austria AG

View source ↗

Summary

Kiovig (human normal immunoglobulin IVIg) has been authorised by EMA for multiple indications including immune thrombocytopenic purpura, bone marrow transplanta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Transplantation
• Guillain-barré Syndrome
• Immunologic Deficiency Syndromes
• Mucocutaneous Lymph Node Syndrome
• Purpura Thrombocytopenic Idiopathic

Drugs mentioned

• Kiovig (human normal immunoglobulin (IVIg))

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic;Bone Marrow Transplantation;Immunologic Deficiency Syndromes;Guillain-Barre Syndrome;Mucocutaneous Lymph Node Syndrome. MAH: Takeda Manufacturing Austria AG. Decision date: 24/06/2022